CPTAC (CLINICAL PROTEOMIC TUMOR ANALYSIS CONSORTIUM)
Central National Biobank (Сenabi) is a member of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) scientific program, in terms of human biosamples collections’ creation (tissues and fluids of cancer patients) for genetic, proteomic and other studies.
CPTAC is a collaborative program of the National Cancer Institute (NCI) and the National Institutes of Health (NIH, USA) and many academic and clinical centers around the world. Following pilot studies of colorectal carcinoma, breast and testicular carcinoma, the CPTAC program has been extended to other 9 major cancers, including non-small cell lung cancer, head and neck cancer, renal cell carcinoma, glioblastoma, and acute myeloid leukemia.
As part of the CPTAC project, the results of molecular analysis of all quality-tested samples will be included in a detailed, accurate and publicly available database that will improve our ability to diagnose, treat and prevent cancer. Proteomic profiles, molecular traits and changes in signaling pathways will be available for analysis by the scientific community (which may also lead to independent publications).
RHEUMATOID ARTHRITIS AND AUTOIMMUNE DISEASES
Creation of a personalized method for predicting effective treatment of rheumatoid arthritis with genetically engineered biological products
Within the framework of this project, the search for biomarkers-glycoproteins that play an important role in the pathogenesis of RA is proposed. A feature of the project is the use of a unique technology that will allow the analysis of biosamples with the identification of glycoproteins that cannot be determined by other methods. The technique is based on the combination of chemoenzymatic methods with methods of qualitative and quantitative proteomic analysis.
Preliminary experiments on the study of biosamples of a pilot group of patients with RA, in the creation of which Cenabi took part, showed that the use of this technique allows us to detect similar relationships of protein profiles, which, in turn, shows the advisability of continuing the research proposed by this project.
It is expected that the scientific result of the project will be a revealed set of glycoproteins, which are specific biomarkers – predictors of the response to genetically engineered biological drugs therapy, primarily inhibitors of tumor necrosis factor alpha (TNFα). Based on the predicted results, it is possible to create a diagnostic test in the form of a protein biochip or ELISA panel, which allows solving the problem of inefficient spending and inadequate therapy.
Thus, the project aims to solve the scientific, therapeutic and socio-economic problems of managing patients with RA that are relevant on a global scale.